• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·France·Healthcare·CLARI.PA
Share

Clariane SE Stocks

€ 4.05Last Updated 16.07.2026

Issuer Rating

4/7
Performance

Favourable

Risk

Moderate

Recommendation

Hold

Market Cap

€ 1.62B

€ 4.05
Key Takeaways

Risk factor

High price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Clariane SE, established in Paris, France, in 2001 and known as Korian until its rebranding in June 2023, specializes in delivering comprehensive medical and non-medical care and support. The company serves senior citizens and individuals facing either temporary or chronic health challenges through a diverse range of provisions. These offerings encompass residential facilities like long-term nursing homes, specialized medical clinics, and senior living communities, including assisted living and co-housing arrangements. Furthermore, Clariane extends its services to include in-home care, various support programs, and hospitalization. Its operational footprint spans multiple European nations, including France, Germany, Italy, Spain, the Netherlands, Belgium, and the United Kingdom.

Company Valuation

Undervalued
6/7

Based on key historical and expected multiples, the stock is undervalued relative to its peers. Specifically, the stock is fairly valued on P/E, neutral on EV/EBITDA, und

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Favourable
6/7

The average target price of CLARI.PA is 4.72 and suggests 16.5% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

18.07.2026 16:01

Small caps last week: Papa John's doubts, Perfect goes private, LLY-AtaiBeckley deal

18.07.2026 13:01

IBM's Worst Day, SK Hynix's Record Plunge, and the "Earnings Bubble" in AI

18.07.2026 03:31

Meta Is in Talks with Anthropic to Lease Data Centers for $10 Billion — The New York Times

18.07.2026 01:33

U.S. stocks closed lower. Chipmakers had their worst week in more than a year.

18.07.2026 00:58

Adidas won the marketing battle against Nike at the World Cup. Investors took note.

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026